Published • loading... • Updated
Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship will expand free genetic testing and provider support as more than 90% of Alpha-1 cases remain undetected, officials said.
- On Friday, Durham-based nonprofit AlphaDetect announced global healthcare company Grifols as its inaugural industry sponsor to accelerate detection of Alpha-1 Antitrypsin Deficiency.
- More than 90% of affected individuals remain unidentified despite potential for irreversible liver and lung damage, while clinical guidelines recommend testing for patients with COPD, treatment-resistant asthma, or unexplained liver disease.
- Grifols' sponsorship builds on a three-decade-long commitment to the Alpha-1 community, which has already seen more than 1.5 million people screened through the company's testing program.
- Scott Santarella, CEO of the Alpha-1 Foundation, said "By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on A1F's mission of improving their lives."
- The Alpha-1 Foundation has invested over $100 million to support research and programs at 130 institutions worldwide, while AlphaDetect provides free genetic testing to eliminate barriers to detection.
Insights by Ground AI
34 Articles
34 Articles
Coverage Details
Total News Sources34
Leaning Left4Leaning Right4Center10Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 22%
C 56%
R 22%
Factuality
To view factuality data please Upgrade to Premium
